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ABSTRACT
Aims The United Kingdom and Australia have developed highly divergent policy responses to electronic nicotine
delivery systems (ENDS). To understand the historical origins of these differences, we describe the history of tobacco
control in each country and the key roles played in setting ENDS policy in its early stages by public health regulations
and policy networks, anti-smoking organizations, ‘vaper’ activist networks and advocates of harm reduction policies
towards injecting drug use. Methods We analysed key government reports, policy statements from public health
bodies and non-government organizations (e.g. cancer councils and medical organizations) on ENDS; submissions to
an Australian parliamentary inquiry; media coverage of policy debates in medical journals; and the history of tobacco
control policy in Australia and England. Key discourses about ENDS were identified for each country. These were
compared across countries during a multi-day face-to-face meeting, where consensus was reached on the key
commonalities and divergences in historical approaches to nicotine policy. This paper focuses on England, as different
policy responses were apparent in constituent countries of the United Kingdom, and Scotland in particular.
Results Policymakers in Australia and England differ markedly in the priority that they have given to using ENDS
to promote smoking cessation or restricting smokers’ access to prevent uptake among young people. In understanding
the origins of these divergent responses, we identified the following key differences between the two countries’
approaches to nicotine regulation: an influential scientific network that favoured nicotine harm reduction in the
United Kingdom and the absence of such a network in Australia; the success of different types of health activism both
in England and in Europe in opposing more restrictive policies; and the greater influence on policy in England of the
field of illicit drug harm reduction. Conclusions An understanding of the different policy responses to electronic
nicotine delivery systems (ENDS) in England and Australia requires an appreciation of how actors within the different
policy structures, scientific networks and activist organizations in each country and region have interpreted the
evidence and the priority that policymakers have given to the competing goals of preventing adolescent uptake and
encouraging smokers to use ENDS to quit smoking.
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INTRODUCTION
Electronic nicotine delivery systems (ENDS) [1] are a con-
troversial new technology which has provoked strongly
polarized responses within the field of tobacco control
[1,2]. Policymakers in Australia have banned the sale of
ENDS in order to prevent their uptake among youth, while
those in the United Kingdom have encouraged smokers to
use ENDS for smoking cessation or harm reduction [3].
These divergent policies are rooted in disagreements about
whether ENDS are likely to produce greater reductions in
tobacco related harm in the population by diverting
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smokers to a safer route or whether they will increase
aggregate harm by recruiting new smokers and stopping
smokers from quitting [4].
In England, policymakers have embraced the potential
for ENDS to reduce tobacco-related harm by encouraging
smokers to use ENDS to quit smoking or as a long-term
substitute for cigarettes [5]. They have accordingly regu-
lated ENDS in ways that facilitate smokers’ access. In
Australia, by contrast, public health authorities have used
drugs and poisons regulations to impose an effective ban
on the sale of vaping products that contain nicotine [6].
As will be shown below, both policies enjoy the strong sup-
port of key stakeholders in each country. There is a minor-
ity of dissenters within the public health communities in
each country, with the dissident view in the United
Kingdom the dominant view in Australia and vice versa.
This paper explores the historical reasons for these
striking policy differences.We begin by giving a detailed de-
scription of the policies towards ENDS in England and
Australia and briefly explain how policymakers have justi-
fied these policies in each country. We then describe the or-
igins of these policies in the history of tobacco control in
each country, highlighting the important role played by in-
fluential policy actors and major research and policy net-
works. We briefly describe the ‘pre-history’ of attitudes
towards the concept of ‘safer smoking’ within networks of
researchers and public health advocates in leading na-
tional institutions and the differing levels of support for
the use of nicotine to assist smoking cessation. We outline
the roles that anti-smoking activist networks have played
in each country and at regional level. We also discuss the
extent to which personnel involved in harm reduction
responses to drugs and HIV have, or have not, provided
support for the use of ENDS in tobacco harm reduction in
each country.
OUR APPROACH TO ANALYSIS
Our approach focused on the methodology of historians,
using contemporary history approaches, primarily the
use of documentary sources. One difference from social
science disciplines is that historians do not start out with
a hypothesis which they are testing. The approach is induc-
tive through interaction with the source material [7–9].
In each country, we reviewed the arguments and
evidence cited in major reports and policy statements by
government agencies and in submissions to parliamentary
inquiries. A detailed content analysis of one of these parlia-
mentary inquiries has been published elsewhere [2]. We
also examined public statements made by leading public
health bodies and non-government organizations (e.g. can-
cer councils, medical organizations and heart foundations)
in each country [10]. We supplemented these data with
arguments presented for and against ENDS policies in me-
dia stories and in the leading medical journals in each
country.
We focused upon key time-points for developments in
ENDS policy and the justifications that were provided for
these policies by key policy actors. We also paid attention
to the concept of pre-history and its impact as developed
through work on HIV/AIDS [11,12]. This approach
argues that contextual issues, the existence of networks,
approaches and structures powerfully affect responses to
new but related policy problems We drew upon histories
of tobacco control policy in each country to understand
the pre-history of these differences in policy approaches to
ENDS between the two countries. Commonalities and dif-
ferences across countries were compared in a multi-day
face-to-face meeting between the investigators. The meet-
ing arrived at a consensus though discussion on key com-
monalities and divergences in historical approaches to
nicotine policy in Australia and the United Kingdom.
Summaries of the policy situation in each country were
prepared and these were used to produce this paper. There
have been different policy views in constituent countries of
the United Kingdom, notably England and Scotland, which
is why England is our main focus. Some agencies are
UK-wide and European Union (EU) regulation applies to
the whole of the United Kingdom, so at times a UK policy
perspective is taken.
ENDS POLICIES IN THE UNITED
KINGDOM
The United Kingdom primarily regulates ENDS as
tobacco-related consumer products. ENDS may also be
licensed as medicines, but no licensed products have been
marketed. When ENDS first came onto the market as
consumer products they were subject to product safety
regulations. In June 2013, on advice from the Medicines
and Healthcare Products Regulatory Agency (MHRA), a
UK-wide agency, the government proposed to regulate all
non-tobacco nicotine products, including ENDS, as medi-
cines. The government later decided against policy for a
number of reasons, the major one being that membership
of the EU required the United Kingdom to comply with
the regulations mandated under the EU Tobacco Products
Directives (TPD). These regulations also fitted with the
preference of the Cameron government (on the advice of
its Behavioural Insights Team, the ‘nudge unit’) for the
use of ‘light touch’ regulation to encourage smokers to
use ENDS as cessation aids and long-term smoking
substitutes [13].
The European Commission had also intended to use
medicinal licensing as the entry route for ENDS, but this
approach was voted down by the European Parliament
on 8 October 2013. The Parliament decided instead that
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ENDS would be regulated like tobacco. The policy change
in the parliament was purported to be brought about by
an alliance of vapers, who made good use of social media,
to obtain the support of Conservative and other MEPs, par-
ticularly those from Italy and Germany. In 2014, passage of
the European TPD (2014/40/EU) placed limits on the sale
and merchandising of tobacco and tobacco-related prod-
ucts in the EU. In 2016, a revised TPD updated regulations
on tobacco products and set new regulations. These
required medical licensing if therapeutic claims were
made for ENDS products or if they contained more than
20 mg/ml of nicotine. They also placed limits on the sale
and merchandising of tobacco and tobacco-related prod-
ucts in the EU. The European Parliament approved these
regulations in February 2014. They prohibited the use of
health or cessation claims when advertising ENDS, and
set limits on the maximum concentration of nicotine
allowed in liquids (less than 20 mg), and the maximum
volumes of liquid that could be sold. They also required:
child-proof packaging of e-liquids, specified purity of ingre-
dients, devices that delivered consistent doses of vapour
and disclosure of ingredients and nicotine content.
Regulators were empowered to act if these regulations
were not met [14]. The Tobacco Products Directive pro-
hibits all forms of advertising capable of crossing borders.
In England, the Committee on advertising practice has pro-
duced guidelines which balance the protection of minors
and the promotion of new low-risk products to consumers.
From 2015 restrictions on age of sale (18 years) and adver-
tising were introduced with the support of researchers.
Leading tobacco control researchers supported the
change in ENDS policy in a series of reports. This included
Public Health England (PHE), a new organization covering
England only, that was created when the government de-
volved public health to local authorities and out of National
Health Service (NHS) control in 2013. PHE produced a se-
ries of reports and evidence updates in 2015 [5] and 2018
[15]. PHE also published a joint statement: ‘E cigarettes: an
emerging public health consensus’ [16], that was
supported by the following public health bodies: Action
on Smoking and Health (ASH); Association of Directors of
Public Health; British Lung Foundation; Cancer Research
UK; Faculty of Public Health; Royal College of Physicians;
the Royal Society for Public Health; the UK Centre for
Tobacco and Alcohol Studies; and the UK Health Forum.
The Royal College of Physicians Tobacco Advisory
Group (RCPTAG) has been an influential supporter of
ENDS. Its 2000 report on nicotine addiction called for the
creation of a nicotine regulatory authority [17] and
RCPTAG advocated for tobacco harm reduction in 2007
and 2018 [18,19]. In its 2016 report, ‘Nicotine without
smoke: tobacco harm reduction’, it concluded that ENDS
were likely to benefit public health in the United Kingdom
[20]. They argued that smokers should be encouraged to
use them and the public reassured that ENDS were much
safer than smoking cigarettes. The British Medical Associa-
tion supported the use of ENDS for cessation in 2017 [21]
and 2018 National Institute for Health and Care Excel-
lence (NICE) guidelines on smoking and harm reduction
supported their use for cessation, if other methods had
failed [22].
In 2017, the House of Commons Science and Technol-
ogy Committee examined the evidence on the impact of
ENDS on human health (including their effectiveness for
smoking cessation), the suitability of regulations guiding
their use and the financial implications of a growing mar-
ket on business and the NHS. Its report supported ENDS
as a form of tobacco harm reduction. The Committee
concluded that: ‘Some aspects of the regulatory system
for e-cigarettes appear to be holding back their use as a stop
smoking measure’ and recommended that ENDS regula-
tions be liberalized [23].
PUBLIC HEALTH OPPOSITION TO
ENGLISH ENDS POLICY
Some leading public health figures have criticized ENDS
policy. Martin McKee and Simon Capewell [24,25] criti-
cized PHE’s claim that ENDSwere 95% safer than smoking
cigarettes. They argued that the estimate was based on a
2013 publication that could not be trusted, because its
funders and some authors had links to the ENDS and to-
bacco industries. They highlighted the potential adverse
health effects of chemicals in e-liquids and the risk that
ENDS would serve as a gateway to cigarette smoking in
young people. In their view, ENDS should only be available
as approved medical devices. A similar stance was adopted
by the then president of the Faculty of Public Health, John
Ashton [26].
THE DEVELOPMENT OF ENDS POLICY IN
AUSTRALIA
In Australia, the sale of nicotine vaping liquid has been
banned as a consequence of classifying nicotine as a
Schedule 7 ‘dangerous poison’. Nicotine can only be sold
if one of the following exemptions applies: (a) it is in prepa-
rations for animal treatment (with 3% or less nicotine); (b)
it is in preparation for human therapeutic use; or (c) it is in
tobacco prepared and packed for smoking. Nicotine as a
smoking cessation aid is included under exemption (b).
These products are classified as Schedule 4 (prescription-
only medicine) unless they are delivered through the oral
mucosa or transdermally, in which case they are available
without a prescription [27].
In Australia, medicines and other therapeutic goods
must be listed on the Australian Register of Therapeutic
Goods (ARTG) before they can be used as medicines. A
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listing on the ARTG requires evidence that ENDS are safe
and effective in clinical trials for smoking cessation and
meet other requirements for a therapeutic good, such as
conformity with therapeutic goods manufacturing stan-
dards. The financial resources required to meet these re-
quirements are major disincentives to manufacturers
applying to have ENDS approved as a medicine in the small
Australian market.
Nicotine e-liquids can be obtained in Australia as unap-
provedmedicines if individuals have amedical prescription.
This allows nicotine e-liquid to be imported for personal use
or to have it compounded by a pharmacist. Vaporizers can
be sold in all states apart from Western Australia (which
has banned their sale). Vaping liquids that do not contain
nicotine can be sold as consumer products, under the same
restrictions that apply to tobacco products. Smoke-free leg-
islation applies to ENDS, and these laws are enforced by
state health departments. Several ENDS vendors have been
prosecuted and fined and e-liquids imported for personal
use have been seized [28]. ENDS users are understandably
confused about the laws covering the use of vaping
products with and without nicotine [29].
In Australia, a series of national tobacco strategies to
guide tobacco control policymaking have been produced
by an inter-governmental committee in consultation with
government and non-government stakeholders, such as
health and medical organizations. ENDS emerged during
the period covered by the 2004–2009 national tobacco
strategy, which anticipated the development of new
non-medicinal nicotine products that were referred to in
the strategy as ‘tobacco substitutes’, ‘other nicotine prod-
ucts’ and ‘alternative nicotine delivery systems’. Objective
4 of the strategy supported harm-reduction approaches
(‘where feasible, to reduce harm associated with continu-
ing use of, and dependence on, tobacco and nicotine’),
which were also described as one of the three pillars of
Australian tobacco control policy, together with supply
and demand reduction strategies. Examples of how to
achieve this policy objective were provided, including the
development of a framework that ‘would coordinate regu-
lation of tobacco products and products designed to replace
tobacco products by:
• forcing the pace of innovation towards less harmful and,
if feasible (and if deemed desirable), less addictive tobacco
products;
• controlling the price and the accessibility of tobacco
products and products that would replace tobacco
products consistent with inherent harmfulness; and
• creating incentives to market tobacco products and
products that would replace tobacco products in ways
that minimize overall population harm’ [30].
In the 2007 federal election the Labor party, led by
Kevin Rudd, was elected to replace the Liberal National
Coalition government. The Rudd government established
an Australian National Preventative Health Agency in
2009 and a National Preventative Health Taskforce,
chaired by Rob Moodie and Mike Daube, to develop a
National Preventive Health Strategy. Mike Daube chaired
the Taskforce’s tobacco expert advisory group. The next
National Tobacco Strategy (2012–18) retained objective
4 from the previous strategy, but was much more negative
about lower-risk products than the previous strategy. It
identified ‘a need to better understand the potential risks
and/or benefits of these products, determine whether there
is a need to increase restrictions on their availability and
use, and identify the most appropriate policy approach for
Australia’. No evaluation of the 2004–09 NTS was
published, so there is no public explanation for the change
in policy direction.
There was very little public input into the formulation
of Australian ENDS policy. State and federal officials devel-
oped policy on the advice of tobacco control advocates
and health and medical organizations [31]. The Common-
wealth Health Department commissioned reviews of the
policy in 2012 and 2014 but did not solicit public submis-
sions and did not publish either report [31].
In 2014, agitation by Australian vaper organizations
prompted state and federal governments to commission in-
quiries into ENDS, some of which invited submissions [31].
The majority of submissions came from vapers who re-
ported that ENDS had assisted them to quit smoking and
who wanted easier access to ENDS. By contrast, submis-
sions from public health and medical organizations all sup-
ported the ENDS sales ban. They emphasized that allowing
ENDS to be sold as consumer products would increase
youth uptake of smoking and argued that ENDS would be
used by the tobacco industry to discourage smokers from
quitting and recruit youth to smoking [31].
Australian ENDS policy enjoys bipartisan support from
the Liberal National coalition government and the Labor
opposition. A minority of centre-right Australian politi-
cians have argued that ENDS should be sold as consumer
products. These include free market advocates within the
Liberal party, a member of a libertarian party and indepen-
dent MPs [31,32]. The Australian Greens support super-
vised injecting rooms, drug checking and the legalization
of recreational cannabis use, but they have not supported
more liberal ENDS policies.
A House of Representatives inquiry into e-cigarettes in
2017 attracted a large number of submissions from public
health researchers, medical organizations and the public
[33]. Nearly all (97%) of the 259 public submissions from
vapers wanted to legalize access to ENDS products that
contain nicotine. Public health and medical organizations
overwhelmingly supported the ban on the sale of ENDS. A
sales ban was supported by all State and Federal Health
Departments, state and national cancer councils, the
National Heart Foundation, the Thoracic Society of
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Australia and New Zealand and the Australian and New
Zealand Public Health Association. The Royal Australian
and New Zealand College of Psychiatrists, RANZCP, was
a notable exception, arguing that medicinal regulation
or regulation as tobacco products would restrict access
to ENDS for people with mental illnesses who have a high
prevalence of cigarette smoking. A few public health
researchers (including two of the authors, C.G. and W.
H.) made submissions in support of the sale of ENDS to
adults (under more restrictive regulations than tobacco
products) [34].
In 2018, the Committee’s majority report supported
the sales ban on ENDS and recommended an evenmore re-
strictive national approach to regulating nicotine-free
vaping products [33]. The majority argued that there
was insufficient evidence that ENDS were effective cessa-
tion aids, and that the possibility that ENDS may serve as
a gateway to smoking among young people justified a sales
ban in keeping with a precautionary principle. Two dis-
senting reports from three members of the Liberal Party
recommended that nicotine in ENDS should be regulated
as consumer products, with ‘restrictions based on those
in place in the EU’ [33].
The historical origins of ENDS policies in the United
Kingdom and Australia
In the remainder of the paper, we offer some provisional
historical explanations for why such divergent ENDs poli-
cies were adopted in Australia, and specifically England,
within the United Kingdom despite their shared history of
tobacco control policies.
The failure of the safer cigarette and the rejection of
tobacco harm reduction
The pre-history of tobacco control might have led one to
expect that Australia and the United Kingdom would have
developed similar policies towards e-cigarettes. Both had a
pre-history of rejecting ‘safer smoking’ and both have
adopted stringent public health policies towards tobacco
smoking. Public health policy in both Australia and the
United Kingdom between the 1950s and the 1970s had
supported research to produce a safer smoking product
by identifying and removing the harmful constituents in
tobacco. This strategy failed in the case of low-tar ciga-
rettes because of compensatory smoking [35–38], and
the public health community largely abandoned tobacco
harm reduction and banned the sale of oral snuff in the
United Kingdom and of chewing tobacco and oral snuff
in Australia [31]. Some leading figures in tobacco control
cite this history as a major reason for their opposition to
ENDS [39].
In both countries, leading tobacco control advocates
successfully campaigned for policies to reduce the demand
for tobacco by: raising tobacco taxes, banning tobacco
advertising, educating smokers about the risks of smoking
(via cigarette pack warnings and mass media campaigns)
and restricting places where cigarettes could be smoked
[35,40,41].
The major actors in the policy networks that success-
fully campaigned for these policies have been influential
opponents of ENDS. In Australia they include Mike Daube
and Simon Chapman, who have publicly supported the
sales ban on ENDS [39,42]. Daube was the second director
of ASH in the United Kingdom in the 1970s and he has
since held senior roles in the Australian Council on
Smoking and Health, the Public Health Advocacy Institute
of Australia and the Australian Government’s National
Preventive Health Agency [35,43]. Chapman is an Emeri-
tus Professor of public health who also has a long history as
an anti-smoking activist, including as a proud founding
member of BUGAUP in Australia, which spray-painted
anti-smoking graffiti on cigarette advertising billboards
[44]. He was also a member of the National Preventative
Health Taskforce tobacco expert advisory group chaired
by Daube. McKee in the United Kingdom shares their
views, and the three have co-authored editorials and par-
liamentary submissions [42,45]. Based on the pre-history
of safer smoking alone, one might have expected both
countries to be hostile to e-cigarettes.
TOBACCO HARM REDUCTION
NETWORKS IN ENGLAND AND
AUSTRALIA
However, there was one crucial aspect of the pre-history of
the tobacco issue on which the two countries radically dif-
fered: the level of support for the use of nicotine in tobacco
harm reduction.
An influential tobacco policy network was established
in London at the Institute of Psychiatry in the 1970s that
adopted a more positive view of tobacco harm reduction
using nicotine. It was led by the psychiatrist Michael
Russell, in the Addiction Research Unit, who set out to de-
velop safer forms of smoking to help those who could not
quit because of nicotine dependence. Russell’s advocacy of
harm reduction using safer forms of nicotine was not pop-
ular in mainstream public health, but the psychologists he
trained later became influential actors in UK policy on
ENDS; namely, Ann McNeill, Robert West, Martin Jarvis
and Peter Hajek [35,46]. Their views later received support
from the Royal College of Physicians, and a leading
academic and tobacco control expert, John Britton, a respi-
ratory physician who influenced the policy advice that the
‘nudge unit’ gave to David Cameron [13].
In Australia, by contrast, psychiatrists and psycholo-
gists have not been as involved in tobacco control or
smoking policy until very recently, when the RANZ College
of Psychiatrists supported the use of ENDS to reduce the
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high prevalence of heavy smoking among their patients.
This reflected an increased focus upon improving the phys-
ical health of people living with a mental illness, such as
the Equally Well Consensus Statement [47]. A minority of
prominent Australian tobacco control advocates, Nigel
Gray and Ron Borland, advocated for tobacco harm reduc-
tion using less harmful nicotine products [48,49]. Both
worked for the Cancer Council of Victoria (CCV) (Gray as
the Director 1968–95 and Borland as a researcher
1986–2019). The CCV has since strongly supported the
ENDS sales ban [50]. For these reasons, a tobacco harm
reduction network was not as well developed in Australia
as in England.
The pre-history of nicotine for cessation and harm
reduction
In England, another crucial difference was a pre-history of
the use of nicotine in cessation treatment in a
well-established network of stop smoking services.
Michael Russell & Ove Ferno (the manufacturer of nico-
tine gum) introduced nicotine-assisted cessation into the
United Kingdom [35]. By themid-1990s, the nicotinenasal
spray and gum could be prescribed on the NHS, advertising
of gumwas allowed in 1998 andNRTwas sold to the public
in two strengths and transdermal patches. In 2006, an
MHRA committee on nicotine regulation concluded that:
‘Overall, the benefits of quitting smoking clearly
outweighed any risk there may be with NRT’ [51]. In
2006, NRT was licensed for temporary abstinence and for
long-term use in 2009 [46]. Specialized NHS smoking ces-
sation services were established from the 1970s/80s and
developed expertise in helping heavy smokers to quit [35].
In 1999 globally unique comprehensive stop smoking ser-
vices were set up with a major financial investment as part
of the Labour government’s tobacco control strategy.
In Australia, by contrast, NRT was only made a
subsidized medicine in 2011, although bupropion and
varenicline were subsidized in 2001 and 2008, respec-
tively. Formal quitting assistance has largely been provided
by free telephone Quitlines in each state/territory sup-
ported by the provision of self-help materials on govern-
ment and non-governmental organization (NGO)
websites. Simon Chapman has questioned the need for
medication-assisted cessation services, arguing that unas-
sisted quitting is the most effective method to quit smoking
[52]. Unlike England, NRT has not been recommended for
long-term harm reduction use by Australian smokers.
The influence of illicit drug harm reduction
Harm reduction influences from the drugs field and a
cross-over of personnel also had more of an influence in
England than in Australia.
In the United Kingdom, harm reduction in the illicit
drug field, where Scotland was also a prominent player,
provided an early stimulus for discussions of harm reduc-
tion in the tobacco field. In 1997AnnMcNeill gave a paper
on tobacco harm reduction to the Society for the Study of
Addiction (SSA). A more direct connection was formed
between ENDS and drugs harm reduction after PHE was
created by combining the National Treatment Agency
(from the alcohol and drugs field) with the Health Protec-
tion Agency and other agencies and covering England only.
Trends within the drug field impacted upon tobacco. The
transfer of a tobacco post to PHE from the Department of
Health enabled liaison between tobacco and the drug and
alcohol treatment sectors. The appointment of Martin
Dockrell was important because he had been policy direc-
tor of ASH, and in the 1980s and 1990s worked on
injecting drug use and harm reduction invarious organiza-
tions. His appointment helped a harm reduction approach
to ENDS to flourish in England in the health bureaucracy
and among networks of researchers.
In Australia, those involved in harm reduction for
drugs had few connections with the tobacco field. A
researcher–clinician, Alex Wodak, who pioneered harm
reduction in the illicit drugs field, has publicly supported
tobacco harm reduction and some individuals and organi-
zations that work in the addictions field made submissions
to the House of Representatives inquiry advocating ENDS
as a way to reduce the high prevalence of smoking in their
patient populations [33]. Other influential public health
figures who supported illicit drug harm reduction policies
in the 1990s have opposed the use of ENDS for harm
reduction [53].
The role of activist organizations
The role of anti-smoking activism has historically been ex-
tremely important in the tobacco field, and this was again
the case with e-cigarettes in England but not in Australia.
Support for vaping came from English ASH, a long-
established, anti-tobacco health activist organization [35].
ASH opposed tobacco harm reduction in the 1970s (under
Mike Daube) but changed its stance in the late 1990s, first
under Clive Bates as Director, and later under Deborah
Arnott (Director from 2004), with input from Martin
Dockrell. ASH first supported tobacco harm reduction
using NRT and later the use of ENDS [54].
Vaper activists also played an important role in develop-
ing UK’s ENDS policy in Europe. Prosmoking groups in the
past were primarily tobacco industry-funded, but the
vaping activists who formed the New Nicotine Alliance ini-
tially avoided affiliating with or receiving any funding from
the tobacco industry, although they may have later
accepted funding from Philip Morris International’s Smoke
Free World Initiative.
6 Virginia Berridge et al.
© 2021 The Authors. Addiction published by John Wiley & Sons Ltd on behalf of Society for the Study of Addiction. Addiction
Vaper activist groups formed in Australia but have been
much less influential in policy. The now defunct Australian
arm of the New Nicotine Alliance (NNA AU) made submis-
sions to government inquiries and unsuccessfully applied to
the TGA to have nicotine vaping products exempted from
Schedule 7 of the Poisons Standard. AnAustralian Tobacco
Harm Reduction Association (ATHRA), led by a general
practitioner who specializes in tobacco cessation, Colin
Mendelsohn, has advocated for smokers to have easier ac-
cess to nicotine vaping products. The public impact of these
advocacy groups has been limited by the success of public
health opponents of ENDS in portraying supporters of
ENDS as affiliated with the tobacco industry (or vaping
companies which are equated with the tobacco industry)
[55]. NNA AU stated that they have not taken any funding
from the tobacco or vaping industry. ATHRA accepted
funds from vaping companies to establish its website, but
it has since adopted a policy of not accepting funding from
the vaping industry.
An Australian branch of ASHwas created in the 1980s
(with Mike Daube as Director) but it was disbanded in
2013 largely because the policies it advocated for had been
implemented [56]. Its advocacy role has been taken on by
state and federal cancer councils and the Australian
Medical Association, all of which have supported the ban
on ENDS sales. Australia did not, as a result, have an orga-
nization such as English ASH that supports tobacco harm
reduction.
LIMITATIONS
Amajor limitation of our analysis of the origins of policy in
Australia was that we had to rely largely upon public doc-
uments. Australian ENDS policy was made by officials with
no public input and commissioned reviews of the policy
have not been published.Wewere unable to access govern-
ment archival material, as this is covered by the 30-year
rule in England. Interviews were carried out in England,
but have not been used in this paper for the purposes of
consistency inmethodology. As a result, the paper is neces-
sarily a first pass at an analysis of some of the major histor-
ical factors that contributed to the striking difference in
policy directions between Australia and the United
Kingdom. Further research is clearly warranted as more
documents are made public and when policymakers, who
may be reluctant to discuss polices decided in confidence,
are prepared to be interviewed about the origins of these
policies.
CONCLUSION
A recent editorial in Nature predicted that ‘policies on
e-cigarettes will be built on evidence and collaboration’
[57]. Our analysis suggests that this may be an optimistic
view, because the evidence has been, and is likely to con-
tinue to be, evaluated very differently by the very different
research and policy networks in Australia and England.
For example, proponents and opponents of harm reduction
using ENDS have disagreed about the strength of the evi-
dence on the effectiveness of ENDS for smoking cessation.
They also fiercely disagreed on whether ENDS is already
serving, or will in future serve, as a gateway to cigarette
smoking in young people. These divergent understandings
of the contested evidence have been refracted through pol-
icy networks, national government structures and institu-
tions that, for historical reasons, have given very different
priority to the goals of promoting cessation among smokers
and preventing the youth uptake of smoking. They have
also given different emphasis to the role of nicotine in
smoking cessation. These historical factors have produced
the highly divergent ENDS policies in Australia and the
United Kingdom that are evident today.
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